XML 165 R38.htm IDEA: XBRL DOCUMENT v3.25.3
Summary of Significant Accounting Policies (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2025
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Mar. 31, 2022
Summary of Significant Accounting Policies [Line Items]              
Other income     $ 200 $ 3,556 $ 3,556  
Company’s operations     The financial results of the Company’s operations are managed and reported to the Chief Executive Officer, who is considered the Company’s CODM, on a consolidated basis        
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]     Chief Executive Officer [Member]        
Redemption price per share (in Dollars per share)         $ 2    
Deferred offering cost         878  
Recognized income tax percentage         50.00%    
Unrecognized tax benefits          
Additional shares (in Shares) 5,000            
Patents [Member]              
Summary of Significant Accounting Policies [Line Items]              
Estimated useful life         20 years    
Mabwell (Shanghai) Bioscience Co Ltd [Member]              
Summary of Significant Accounting Policies [Line Items]              
Receivables             $ 3,500
Other income   $ 3,500     $ 3,500    
Contingent Earnout Shares [Member]              
Summary of Significant Accounting Policies [Line Items]              
Additional shares (in Shares)         483,333    
AbMed [Member]              
Summary of Significant Accounting Policies [Line Items]              
Ownership interest     82.00%   82.00%    
Preferred Share [Member]              
Summary of Significant Accounting Policies [Line Items]              
Redemption price per share (in Dollars per share)     $ 2